POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).
Potassium chloride replaces potassium ions lost through various routes; potassium is the primary intracellular cation essential for nerve impulse transmission, muscle contraction, and acid-base balance. Dextrose 5% provides caloric support, and lactated Ringer's solution provides electrolytes and buffers. The combination corrects hypokalemia and provides maintenance fluids.
| Metabolism | Potassium is not metabolized; it is eliminated primarily by the kidneys via glomerular filtration and tubular secretion. Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle. Lactate is metabolized to bicarbonate in the liver. |
| Excretion | Renal excretion of potassium is the primary route of elimination (>90%). Under normal conditions, approximately 80-90% of potassium is excreted renally, with the remainder lost via feces (approximately 10%) and minimal loss through sweat. In the setting of intravenous administration, potassium distributes into the body and is ultimately excreted by the kidneys. The kidney adjusts potassium excretion based on dietary intake, acid-base status, and hormonal influences (e.g., aldosterone). Excretion is markedly reduced in renal impairment. |
| Half-life | Potassium does not have a true terminal elimination half-life in the conventional sense because it is an endogenous electrolyte. After a single intravenous dose, the decline in serum concentration is multiphasic, reflecting distribution into cells and subsequent renal excretion. The initial distribution half-life is about 1-2 hours, while the terminal efflux from deep compartments (e.g., bone, muscle) can be prolonged, with a reported mean terminal half-life of approximately 4-5 hours in patients with normal renal function. Clinically, the half-life is extended in renal failure and can exceed 12-24 hours, necessitating cautious monitoring. |
| Protein binding | Potassium is not significantly bound to plasma proteins (<5%). It exists primarily as free ions in serum and interstitial fluid. |
| Volume of Distribution | The apparent volume of distribution of potassium is approximately 0.5–0.7 L/kg in adults, reflecting extensive intracellular distribution (98% of total body potassium is intracellular). The Vd is larger in lean body mass and smaller in obesity. Clinical significance: Changes in Vd affect the dose required to achieve a target serum concentration; for example, in hypokalemia, a larger Vd may require higher doses for repletion. |
| Bioavailability | Potassium chloride is 100% bioavailable when administered intravenously. Oral bioavailability is nearly complete (approximately 90-100% absorbed from the gastrointestinal tract) when given as a solution or effervescent tablet, but sustained-release formulations have reduced bioavailability due to incomplete release. For the IV formulation in this monograph, bioavailability is 100%. |
| Onset of Action | Intravenous administration of potassium results in an immediate increase in serum potassium concentration; however, the clinical effect on cardiac and neuromuscular function is dependent on the rate of infusion. A measurable rise in serum potassium is seen within minutes of starting an IV infusion. The onset of therapeutic effect (e.g., correction of hypokalemia or stabilization of cardiac membrane) is typically within 30 minutes to 1 hour, but time to steady state with continuous infusion may take several hours. |
| Duration of Action | The duration of effect of a single IV dose of potassium is short, as the body rapidly distributes and excretes the ion. For a bolus dose (e.g., 10-20 mEq), the serum potassium level peaks within 30-60 minutes and then declines over the next 2-4 hours. With continuous infusion, a steady state is achieved after approximately 6-12 hours, and the effect persists for the duration of the infusion. After discontinuation, serum potassium returns to baseline over a few hours in patients with normal renal function. Caution: the cardiac effects (e.g., ECG changes) may persist for longer if redistribution is slow. |
| Molecular Weight | 74.55 |
Intravenous infusion; 15 mEq potassium chloride in 1 L of D5LR at a rate not exceeding 10 mEq/hour and 200 mEq/24 hours; typical adult dose is 10-20 mEq/hour, not exceeding 60 mEq/hour in emergencies, with continuous ECG monitoring.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25-50%; GFR 10-29 mL/min: reduce dose by 50-75%; GFR <10 mL/min: avoid potassium supplements or use with extreme caution, maximum 50 mEq/day with frequent monitoring. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce total daily dose by 25%; Child-Pugh C: avoid potassium chloride due to risk of hyperkalemia; use with caution and monitor serum potassium closely. |
| Pediatric use | Intravenous infusion; 0.5-1 mEq/kg/dose, rate not exceeding 0.5 mEq/kg/hour; maximum 3 mEq/kg/day or 40 mEq/m2/day; administered as part of maintenance fluids; adjust based on serum potassium levels and ECG monitoring. |
| Geriatric use | Start at lower end of adult dosing; maximum infusion rate 5-10 mEq/hour; monitor renal function and serum potassium closely; typical dose 10-20 mEq/24 hours in maintenance fluids; avoid rapid administration due to increased risk of hyperkalemia. |
| 1st trimester | Potassium chloride in this formulation is generally considered safe in the first trimester when used at recommended doses for correction of hypokalemia or as a component of maintenance fluids. However, high doses may cause maternal hyperkalemia which could affect fetal cardiac function. No known teratogenicity. |
| 2nd trimester | Safe for use in the second trimester for fluid and electrolyte replacement. Monitor serum potassium to avoid hyperkalemia. |
| 3rd trimester | Safe in third trimester for indicated uses. Avoid excessive potassium administration, especially in preeclampsia or renal impairment, to prevent fetal arrhythmias. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta via active transport; maternal IV administration results in fetal serum potassium levels approximately equal to maternal levels. No known adverse effects at therapeutic doses. |
| Breastfeeding | Potassium chloride is a normal component of breast milk. Administration of intravenous potassium chloride does not significantly increase milk levels. Use with caution in mothers with renal impairment or those receiving potassium-sparing diuretics. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride is a physiological ion and not teratogenic. Dextrose and lactated Ringer's are standard maintenance solutions. No fetal risks identified with appropriate use. However, maternal hyperkalemia during pregnancy can cause fetal arrhythmias or death, so iatrogenic hyperkalemia must be avoided. No trimester-specific risks beyond those related to maternal electrolyte imbalance. |
| Fetal Monitoring | Monitor serum potassium, glucose, electrolytes, renal function, and fluid balance. In pregnancy, monitor for signs of hyperkalemia (ECG changes, muscle weakness) and hypoglycemia/hyperglycemia. Fetal heart rate monitoring if maternal metabolic disturbance occurs. |
| Fertility Effects | No known effects on fertility. Potassium chloride, dextrose, and lactated Ringer's are physiological substances without reproductive toxicity. |
■ FDA Black Box Warning
Concentrated potassium chloride solutions (e.g., >40 mEq/L or undiluted) must be diluted prior to administration. Rapid infusion may cause fatal hyperkalemia and cardiac arrest. Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia. Monitor serum potassium and ECG continuously during infusion.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAddison's diseaseAcute dehydrationConcomitant use of potassium-sparing diuretics (e.g., spironolactone, eplerenone) unless carefully monitoredK+-sensitive disorders (e.g., periodic paralysis)
| Precautions | Risk of hyperkalemia, especially in patients with renal impairment, severe burns, or acidosis, Cardiac arrhythmias can occur with rapid infusion or excessive potassium administration, Extravasation may cause tissue necrosis; ensure proper IV placement, Monitor serum potassium, glucose, electrolytes, and renal function regularly, Use with caution in patients with heart failure, severe hypovolemia, or metabolic alkalosis |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach, avocados) and salt substitutes containing potassium chloride unless instructed otherwise by your doctor. |
| Clinical Pearls | Administer via central line if concentration >60 mEq/L; peripheral line may cause phlebitis. Monitor serum potassium and ECG during infusion. Potassium overdose can cause hyperkalemia-induced cardiac arrest. Do not use in patients with hyperkalemia, severe renal impairment, or untreated Addison's disease. Lactated Ringer's is contraindicated in lactic acidosis. |
| Patient Advice | This IV solution contains potassium; avoid additional potassium supplements without consulting your doctor. · Report symptoms of hyperkalemia: muscle weakness, irregular heartbeat, tingling in hands/feet. · Inform your healthcare provider if you have kidney problems or are on potassium-sparing diuretics. · Do not stop or adjust infusion rate yourself. |
Loading safety data…